Drug Development

Uncommon Productions' 'Cracking the Code' earns top honors, celebrating the biotech revolution and the power of scientific ingenuity.

Therini Bio's novel drug THN391 enters trials, targeting inflammation in diabetic eye disease, while a next-gen combo therapy aims to redefine care.

Sensorium Therapeutics advances SNTX-2643, a novel anxiety drug, while adding a new CMO and an expert advisory board to guide its clinical journey.

EOM Pharmaceutical gets FDA clearance for a trial on EOM613, a potential first-in-class treatment for cancer cachexia, a severe wasting syndrome.

NEOK Bio begins Phase 1 trials for two bispecific ADCs, a next-gen therapy aiming to outsmart tumor resistance and offer new hope for solid tumor patients.

New preclinical data shows RTY-406 could be a first-in-class therapy for PSC, a progressive liver disease with no effective treatments.

Vanda Pharmaceuticals' rare disease drug gets a key designation in Japan, unlocking major incentives and promising a new treatment for a severe skin disease.

Positive Phase 3 data for oral drug filgotinib offers new hope for thousands of axial spondyloarthritis patients who fail to respond to current therapies.

Ionetix wins FDA approval for its generic prostate cancer imaging agent, a move set to boost access and shake up the competitive radiopharmaceutical market.

MBX Biosciences prepares for the Jefferies conference, with investors eyeing updates on its late-stage hypoparathyroidism drug and promising obesity portfolio.

A biotech firm's novel marine compound, now patented, shows promise in modulating key cell pathways, offering a new strategy against intractable diseases.

Amid promising safety signals, Kazia Therapeutics expands its trial for paxalisib in TNBC, a strategic move offering new hope for a hard-to-treat cancer.

Preliminary data shows IBI363 achieved an 86.4% response rate in advanced lung cancer patients who typically respond poorly to current immunotherapies.

With game-changing Phase III data for iza-bren in breast cancer and a deep pipeline, SystImmune is poised to make a major impact at ASCO 2026.

Gene Solutions' AI-driven multi-omics liquid biopsy platform makes waves at a major oncology conference, finding a ready market in Taiwan.

Pliant Therapeutics heads to ASCO with data on a novel drug designed to reawaken the immune system's attack on advanced, treatment-resistant tumors.

New data shows Moleculin Biotech's Annamycin avoids heart toxicity, a breakthrough that could transform treatment for leukemia and sarcoma patients.

At SLAS 2026, MGI Tech unveiled intelligent platforms for proteomics and clinical automation, signaling a major push to accelerate scientific discovery.

Teva's new once-monthly olanzapine injection could revolutionize schizophrenia care in Europe, offering hope for better treatment adherence and patient outcomes.

A potential first-in-class antibody-drug conjugate for colorectal cancer begins a pivotal trial, aiming to help patients who have run out of options.